Biogen (BIIB) Competitors $127.85 +5.17 (+4.21%) Closing price 04:00 PM EasternExtended Trading$128.40 +0.55 (+0.43%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BIIB vs. AMGN, GILD, IONS, MRNA, PRTA, SAGE, SAVA, VRTX, BMY, and LLYShould you be buying Biogen stock or one of its competitors? The main competitors of Biogen include Amgen (AMGN), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Moderna (MRNA), Prothena (PRTA), Sage Therapeutics (SAGE), Cassava Sciences (SAVA), Vertex Pharmaceuticals (VRTX), Bristol Myers Squibb (BMY), and Eli Lilly and Company (LLY). These companies are all part of the "medical" sector. Biogen vs. Its Competitors Amgen Gilead Sciences Ionis Pharmaceuticals Moderna Prothena Sage Therapeutics Cassava Sciences Vertex Pharmaceuticals Bristol Myers Squibb Eli Lilly and Company Amgen (NASDAQ:AMGN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership. Do institutionals and insiders have more ownership in AMGN or BIIB? 76.5% of Amgen shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 0.7% of Amgen shares are held by insiders. Comparatively, 0.2% of Biogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is AMGN or BIIB more profitable? Amgen has a net margin of 17.39% compared to Biogen's net margin of 15.07%. Amgen's return on equity of 176.11% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Amgen17.39% 176.11% 12.39% Biogen 15.07%14.03%8.32% Does the media refer more to AMGN or BIIB? In the previous week, Amgen had 7 more articles in the media than Biogen. MarketBeat recorded 62 mentions for Amgen and 55 mentions for Biogen. Amgen's average media sentiment score of 1.23 beat Biogen's score of 0.60 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 51 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 22 Very Positive mention(s) 4 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, AMGN or BIIB? Amgen has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Which has stronger earnings and valuation, AMGN or BIIB? Amgen has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmgen$33.42B4.92$4.09B$10.9627.89Biogen$9.68B1.94$1.63B$10.1312.62 Do analysts prefer AMGN or BIIB? Amgen presently has a consensus target price of $308.77, suggesting a potential upside of 1.01%. Biogen has a consensus target price of $186.37, suggesting a potential upside of 45.77%. Given Biogen's higher possible upside, analysts clearly believe Biogen is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amgen 2 Sell rating(s) 12 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.35Biogen 0 Sell rating(s) 21 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.34 SummaryAmgen beats Biogen on 14 of the 17 factors compared between the two stocks. Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIIB vs. The Competition Export to ExcelMetricBiogenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.98B$2.93B$5.49B$9.45BDividend YieldN/A2.49%4.01%4.03%P/E Ratio12.6220.5328.3319.89Price / Sales1.94267.14429.4395.52Price / Cash5.3141.6635.9658.29Price / Book1.117.808.325.67Net Income$1.63B-$55.10M$3.24B$258.18M7 Day Performance0.27%6.40%4.20%3.92%1 Month Performance0.64%16.84%10.16%14.31%1 Year Performance-43.59%3.12%34.69%17.29% Biogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIIBBiogen4.9033 of 5 stars$127.85+4.2%$186.37+45.8%-45.8%$17.98B$9.68B12.627,605Trending NewsAnalyst UpgradeAMGNAmgen4.214 of 5 stars$296.46+0.4%$307.82+3.8%-10.7%$159.28B$33.42B27.0328,000Positive NewsAnalyst ForecastGILDGilead Sciences4.9165 of 5 stars$112.01+2.2%$111.38-0.6%+49.2%$139.36B$28.75B23.5917,600IONSIonis Pharmaceuticals4.5589 of 5 stars$42.36+1.5%$58.25+37.5%-13.1%$6.75B$717.25M-14.181,069Analyst RevisionMRNAModerna4.27 of 5 stars$33.16-1.4%$46.61+40.6%-74.4%$12.83B$3.24B-3.805,800Analyst ForecastPRTAProthena4.0267 of 5 stars$6.41+0.1%$31.50+391.8%-73.3%$345.84M$137.94M-3.09130SAGESage Therapeutics3.387 of 5 stars$9.15-1.3%$8.75-4.4%-27.0%$572.66M$41.24M-1.58690SAVACassava Sciences3.862 of 5 stars$2.17+1.6%$54.50+2,417.3%-77.2%$104.59MN/A-1.4430VRTXVertex Pharmaceuticals4.3935 of 5 stars$473.24+0.9%$511.71+8.1%-6.7%$121.44B$11.02B-120.636,100Positive NewsBMYBristol Myers Squibb4.7038 of 5 stars$47.57+1.5%$57.69+21.3%+9.6%$96.78B$47.64B17.8134,100LLYEli Lilly and Company4.9824 of 5 stars$795.36+0.3%$1,012.56+27.3%-11.1%$753.80B$49.00B64.7247,000Trending News Related Companies and Tools Related Companies Amgen Competitors Gilead Sciences Competitors Ionis Pharmaceuticals Competitors Moderna Competitors Prothena Competitors Sage Therapeutics Competitors Cassava Sciences Competitors Vertex Pharmaceuticals Competitors Bristol Myers Squibb Competitors Eli Lilly and Company Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIIB) was last updated on 7/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredYour blueprint for crypto wealthThe crypto market is heating up, with massive opportunities ahead for those who know where to look. Join u...Crypto 101 Media | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIIB Stock Alerts